SCHEMBL2434951

SCHEMBL2434951

Cc1cc(C#N)c(C(=O)O)cc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
GALR3 O60755 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
LDHA P00338 1/20 0.45
XDH P47989 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
MYC P01106 1/20 0.42
PTPN1 P18031 1/20 0.41
ESR2 Q92731 1/20 0.41
MCL1 Q07820 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28687405 0.81 LMNA (0.51) ALDH1A1GAAHPGDPTPN1
SCHEMBL28685217 0.81 MAOA (0.52) KDM4EALDH1A1HPGDXDHCYP1A2
SCHEMBL28804822 0.76 LDHA (0.57) ALDH1A1LDHAAKR1C3AKR1C2AKR1C1
SCHEMBL2429144 0.76 LDHA (0.49) HPGDLDHACYP1A2CYP2C9CYP2C19
SCHEMBL24868762 0.74 LDHA (0.54) ALDH1A1LDHAAKR1C3AKR1C2AKR1C1
SCHEMBL27967825 0.74 LDHA (0.47) ALDH1A1LDHAAKR1C3AKR1C2AKR1C1
SCHEMBL27587159 0.73 ACMSD (0.58) KDM4EALDH1A1HPGDXDHPTPN1
SCHEMBL10401317 0.73 ACMSD (0.58) XDHPTPN1MCL1
SCHEMBL28693745 0.73 LDHA (0.46) KDM4EALDH1A1HPGDLDHAAKR1C3
SCHEMBL28673517 0.73 ALDH1A1 (0.58) KDM4EALDH1A1HPGDLDHANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102746285-B Compounds and compositions as HEDGEHOG pathway modulators 太阳制药国际公司 2022-01-14 CN disclosed
EP-2363393-B1 Compounds and compositions as hedgehog pathway modulators NOVARTIS AG (CH) 2015-08-12 EP disclosed
US-20150025074-A1 METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES BUONAMICI SILVIA (US) 2015-01-22 US disclosed
EP-2363393-A1 Compounds and compositions as hedgehog pathway modulators IRM LLC (BM) 2011-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025074-A1 METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES MTOR, ULK1, HRAS KDM4E 1283/4885GALR3 3691/4885ALDH1A1 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.